Selective Alpha Adrenergic Receptor Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current alpha adrenergic receptor modulators often have undesirable side effects such as hypotension and sedation, limiting their effectiveness in treating conditions like glaucoma, pain, and hypertension, due to their non-selective binding to alpha-1 and alpha-2 receptors.
Innovation Solution
Development of specific compounds, such as those represented by formulas I, II, III, IV, and V, which act as alpha adrenergic receptor modulators, providing selective agonist or antagonist activity to treat various disorders with reduced side effects by targeting specific receptor subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective alpha adrenergic receptor modulators are used, then broad therapeutic effects are achieved, but undesirable side effects such as hypotension and sedation occur
Solution Approach 1:
The patent segments the alpha adrenergic receptor modulator class into selective subtypes (alpha-1 selective and alpha-2 selective compounds). This segmentation allows the invention to target specific receptor subtypes rather than acting non-selectively on all alpha receptors, thereby achieving therapeutic effects while minimizing side effects associated with non-selective binding.
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular structures that confer selectivity for particular alpha receptor subtypes. By modifying molecular characteristics (such as using specific heterocyclic rings, substituent patterns, and structural motifs), the compounds achieve localized action on target receptors, reducing off-target effects and improving the therapeutic index.
2Productivity
If alpha-2 agonist activity is enhanced, then intraocular pressure reduction and renal flow increase are improved, but plasma catecholamine concentration increases leading to increased heart rate and smooth muscle contraction
Solution Approach 1:
The patent segments alpha adrenergic modulation into selective alpha-1 and alpha-2 agonist/antagonist compounds. By developing alpha-1 selective compounds, the invention avoids activation of alpha-2 receptors that would trigger catecholamine release, thereby achieving therapeutic effects without the harmful feedback of increased plasma catecholamines and subsequent cardiovascular side effects.
Solution Approach 2:
The patent converts the harmful effect of non-selective alpha-2 agonism (which increases plasma catecholamines and causes cardiovascular side effects) into a benefit by developing selective alpha-1 compounds. These compounds achieve the desired therapeutic effects while avoiding the harmful alpha-2 mediated catecholamine release, effectively using selectivity to eliminate the harmful feedback loop.
3Reliability
If alpha-1 antagonist activity is increased, then vasoconstrictor control is improved, but non-selective binding to alpha-2 receptors causes increased plasma catecholamine concentration
Solution Approach 1:
The patent segments alpha adrenergic receptor antagonism into alpha-1 selective and non-selective compounds. By designing alpha-1 selective antagonists with specific molecular structures (such as certain heterocyclic cores and substituent patterns), the invention achieves reliable alpha-1 receptor binding while avoiding alpha-2 receptor interaction, thereby preventing the harmful increase in plasma catecholamine concentration.
Solution Approach 2:
The patent applies local quality by optimizing the molecular structure of alpha-1 selective compounds to enhance affinity for alpha-1 receptors while reducing affinity for alpha-2 receptors. Specific structural features (such as particular ring systems, substituent positions, and molecular geometry) are engineered to create localized interaction with alpha-1 receptors, ensuring selective antagonism without triggering alpha-2 mediated catecholamine release.
Data Source
AI summary
Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.